Haemonetics Corp (NYSE: HAE) flaunted slowness of -3.11% at $84.45, as the Stock market unbolted on Thursday, before settling in for the price of $87.16 at the close. Taking a more long-term approach, HAE posted a 52-week range of $47.31-$87.32.
The Healthcare sector firm’s twelve-monthly sales growth has been 17.48% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 17.48%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 7.53%. This publicly-traded company’s shares outstanding now amounts to $46.75 million, simultaneously with a float of $46.07 million. The organization now has a market capitalization sitting at $3.95 billion. At the time of writing, stock’s 50-day Moving Average stood at $64.07, while the 200-day Moving Average is $64.11.
Haemonetics Corp (HAE) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Haemonetics Corp industry. Haemonetics Corp’s current insider ownership accounts for 1.57%, in contrast to 111.23% institutional ownership. According to the most recent insider trade that took place on Nov 10 ’25, this organization’s Director bought 1,400 shares at the rate of 70.56, making the entire transaction reach 98,784 in total value, affecting insider ownership by 24,757.
Haemonetics Corp (HAE) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.3 per share during the current fiscal year.
Haemonetics Corp’s EPS increase for this current 12-month fiscal period is 7.53% and is forecasted to reach 5.49 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 10.31% through the next 5 years, which can be compared against the 17.48% growth it accomplished over the previous five years trading on the market.
Haemonetics Corp (NYSE: HAE) Trading Performance Indicators
Let’s observe the current performance indicators for Haemonetics Corp (HAE). It’s Quick Ratio in the last reported quarter now stands at 1.03. Alongside those numbers, its PE Ratio stands at $24.64, and its Beta score is 0.29. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.98. Similarly, its price to free cash flow for trailing twelve months is now 15.44.
In the same vein, HAE’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 3.43, a figure that is expected to reach 1.25 in the next quarter, and analysts are predicting that it will be 5.49 at the market close of one year from today.
Technical Analysis of Haemonetics Corp (HAE)
Now, what If we examine the latest scores posted by [Haemonetics Corp, HAE]. During the last 5-days, its volume was better the volume of 0.86 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 76.73% While, its Average True Range was 70.35.
Raw Stochastic average of Haemonetics Corp (HAE) in the period of the previous 100 days is set at 92.83%, which indicates a major rise in contrast to 75.47% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 2.30 that was higher than 1.92 volatility it exhibited in the past 100-days period.
